Genitourinary Cancers Symposium (ASCO GU) | Conference

Cabozantinib Regimens Active Across Multiple Advanced GU Malignancies

February 21st 2017

The combination of cabozantinib and nivolumab, with or without ipilimumab, proved safe and active in advanced genitourinary cancers, particularly urothelial cancer.

Combination Makes First-Line Case for Metastatic PD-L1+ RCC

February 21st 2017

Patients with PD-L1-positive metastatic renal cell carcinoma had a reduction in the risk of progression or death when treated in frontline with the combination of atezolizumab and bevacizumab instead of sunitinib, according to results of a randomized trial.

Dr. Saad on Recent Updates in Active Surveillance in Prostate Cancer

February 20th 2017

Fred Saad, MD, professor and chairman of Urology, director of Genitourinary Oncology, the University of Montreal Hospital Centers, discusses recent updates in active surveillance for patients with prostate cancer.

Dr. Powles on Durvalumab in Urothelial Cancer

February 20th 2017

Thomas Powles, MD, Barts Cancer Institute, discusses durvalumab as a second-line therapy in locally advanced and metastatic urothelial cancer.

Ipilimumab Broadens Nivolumab Activity in Urothelial Cancer

February 19th 2017

Five of 8 patients with metastatic urothelial cancer benefited from the combination of ipilimumab and nivolumab after having no response to single-agent nivolumab.

Pembrolizumab Plus Chemo Shows Promise in Urothelial Carcinoma

February 19th 2017

Combining the PD-1 inhibitor pembrolizumab with chemotherapy induced objective responses in one-third of patients with previously treated metastatic urothelial carcinoma.

Dr. Jonasch on Promise of Immuno-Oncology Agents in RCC

February 18th 2017

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the promise of immuno-oncology agents in sarcomatoid renal cell carinoma (RCC).

Dr. Steinberg on Trial of HS-410 Vaccine in Bladder Cancer

February 18th 2017

Gary Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the immune response results of vesigenurtacel-I (HS-410) vaccine in non-muscle invasive bladder cancer (NMIBC).

Dr. Morris on Bone Biomarkers for Radium-223 in Prostate Cancer

February 18th 2017

Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses bone biomarkers for radium-223 dichloride (Xofigo) in castration-resistant prostate cancer.

Durvalumab Impresses in Advanced Urothelial Cancer

February 18th 2017

The PD-L1 inhibitor durvalumab demonstrated compelling clinical activity and a manageable safety profile as second-line therapy for locally advanced or metastatic urothelial cancer.

Genomic Test Predicts Metastasis, Mortality in Prostate Cancer

February 18th 2017

The genomic-based Decipher test effectively predicted metastasis and prostate cancer-specific mortality from diagnostic biopsy specimens for patients with intermediate- and high-risk prostate cancer.

Dr. Balar on Results of KEYNOTE-052 in Urothelial Cancer

February 18th 2017

Arjun Balar, MD, director, Genitourinary Medical Oncology Progam, NYU Langone Medical Center, discusses the results from the KEYNOTE-053 trial in cisplatin-ineligible advanced urothelial carcinoma.

Olaparib, Durvalumab Combo Active in Prostate Cancer

February 17th 2017

According to preliminary results from an ongoing trial, half of a small group of patients with metastatic castration-resistant prostate cancer had a PSA response during treatment with the PD-L1 inhibitor durvalumab and the PARP inhibitor olaparib (Lynparza).

AR-FL mRNA Correlates With Response to AR-Targeted Therapies

February 17th 2017

According to results of a prospective clinical study, circulating tumor cell mRNA of full-length androgen receptor (AR) correlated with detection of the AR-V7 variant and with response to AR-targeted therapy for castration-resistant prostate cancer.

Dr. Oh on Results of Chemotherapy Versus ARTA in Prostate Cancer

February 17th 2017

William Oh, MD, professor, Mount Sinai Hospital, discusses the results from a trial that compared second-line chemotherapy to alternative androgen receptor-targeted agents (ARTA) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Josh Armenia on Results of Mutated Gene Analysis in Prostate Cancer

February 17th 2017

Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the results of an analysis of significantly mutated genes in prostate cancer.

Dr. Apolo on Study of Cabozantinib Plus Nivolumab and Ipilimumab in Urothelial Carcinoma

February 17th 2017

Andrea B. Apolo, MD, chief of bladder cancer section, National Cancer Institute, discusses the phase I study of cabozantinib (Cabometyx) plus nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with refractory metastatic urothelial carcinoma (mUC) and other genitourinary tumors.

Dr. Hammers on Study of HyperAcute Renal Immunotherapy in RCC

February 17th 2017

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses HyperAcute Renal (HAR) immunotherapy in patients with renal cell carcinoma (RCC).

Dr. Tagawa on IMMU-132 Trial Updates in Urothelial Cancer

February 16th 2017

Scott T. Tagawa, MD, Weill Cornell Medicine/New York-Presbyterian, discusses updated results from the IMMU-132 trial in metastatic urothelial cancer (mUC).

Circulating Tumor DNA Can Advance Personalized Care in mCRPC

February 14th 2017

Up to 94% of patients with metastatic castration-resistant prostate cancer have circulating tumor DNA with at least 1 genetic alteration, suggesting ctDNA could be a noninvasive alternative to traditional tumor biopsies and help personalize treatment in this setting.